Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …

Immunotherapy with checkpoint inhibitors is well established as an effective treatment for
non-small cell lung cancer and melanoma. The list of approved indications for treatment with …

Background Pembrolizumab monotherapy showed durable antitumour activity and
manageable safety in patients with metastatic triple-negative breast cancer. We aimed to …

Background In the phase III IMpassion130 study, atezolizumab plus nab-paclitaxel (A+ nP)
showed clinical benefit in advanced or metastatic triple-negative breast cancer patients who …

Expression of programmed cell death-ligand 1 (PD-L1) is being used as predictive
biomarker for immunotherapy in head and neck squamous cell carcinoma (HNSCC) …

Simple Summary Natural killer cells are innate cytotoxic lymphocytes that play a key role in
the anti-tumor immune response. In the tumor microenvironment, however, the effector …

Breast cancer has historically been a disease for which immunotherapy was largely
unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with …

Immune checkpoint inhibitor therapies targeting PD‐1/PD‐L1 are now the standard of care
in oncology across several hematologic and solid tumor types, including triple negative …

Breast cancer intrinsic subtypes (IS) are biologically distinct entities, characterized by
specific natural gene expression patterns 1, 2. The most widely accepted IS are the Luminal …

Immune evasion is a key strategy adopted by tumor cells to escape the immune system
while promoting their survival and metastatic spreading. Indeed, several mechanisms have …